로딩 중…
StockDiggingStockDigging

LigaChem Biosciences Inc.

141080· KOSDAQ
₩134,600+0.07%
2026-06-19

Price Chart

LigaChem Biosciences Inc.+25.68%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap4.98T KRW
Revenue125.87B KRW
Net Income-151.33B KRW
Total Assets652.93B KRW
Net Assets500.52B KRW
Employees174
Value
P/B9.96x
P/S39.59x
FCF Yield-2.50%
Profitability
ROE-30.23%
ROA-23.18%
Op. Margin-123.37%
Revenue Growth-30.42%
Earnings Growth-225.81%
Financial Health
Debt Ratio30.45%
Total Debt0 KRW
FCF-124.53B KRW
Cash63.48B KRW
Current Ratio10.12x
Performance
1Y Return25.68%
1M Return-2.60%
From 52W High-40.18%
1Y MDD-45.43%
Trading
Volume346,880 shares
Foreign Own.11.49%
Per Share
EPS-3,772 KRW
BPS12,705 KRW

Company Info

CEO 김용주
Employees 174
Founded 2006
HQ 대전광역시 유성구, KR

LegoChem Biosciences, established in 2006 and headquartered in Yuseong-gu, Daejeon, is a research-oriented pharmaceutical company listed on KOSDAQ in 2013. The company developed the medicinal chemistry-based original Antibody-Drug Conjugate (ADC) technology named ConjuALL, driving global commercialization through ADC anticancer drug research and development and technology transfer. Through "Beyond ADC" research, it focuses on developing bispecific antibody ADCs, immuno-oncology drugs, and combination therapies, while also securing stable revenue from medical device and consumable sales.